About us Contacts Drug interactions: 390 212
Drug search by name

Adcirca and Hytrin capsules

Determining the interaction of Adcirca and Hytrin capsules and the possibility of their joint administration.

Check result:
Adcirca <> Hytrin capsules
Relevance: 27.10.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Talk to your doctor before using tadalafil together with terazosin. Combining these medications can lower your blood pressure and increase the risk of dizziness, lightheadedness, fainting, flushing, headache, and nasal congestion. These side effects may also occur with either medication alone and are most likely to be seen at the beginning of treatment, following a dose increase, or when treatment is restarted after an interruption. Let your doctor know if you develop these symptoms and they do not go away after a few days or they become troublesome. Avoid driving or operating hazardous machinery until you know how these medications affect you, and use caution when getting up from a sitting or lying position. In general, your blood pressure should be stable and you should be on a steady dose of one medication before you begin the other. You may need a dose adjustment or your blood pressure checked more often if you take both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

ADJUST DOSE: Tadalafil may potentiate the hypotensive effect of alpha blockers, resulting in symptomatic hypotension in some patients. Tadalafil inhibits phosphodiesterase-5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation that may be additive with that induced by alpha blockers. In 18 healthy subjects taking doxazosin 8 mg daily for at least 7 days, administration of tadalafil 20 mg resulted in significant augmentation of the blood pressure lowering effect of doxazosin, an alpha-1 adrenergic blocker. Specifically, nine patients given tadalafil had either a standing systolic blood pressure of less than 85 mm Hg or a decrease from baseline of greater than 30 mm Hg at one or more time points, compared to three such patients when given placebo. Two significant adverse events (vertigo and dizziness) potentially related to blood pressure effects were reported with tadalafil, compared to none with placebo. No syncope was reported. In a clinical study of healthy male subjects 45 to 78 years of age, administration of silodosin with a single 20 mg dose of tadalafil resulted in increased frequency of positive orthostatic test results during a 12-hour period following concomitant dosing compared to administration with placebo. No events of symptomatic orthostasis or dizziness were reported in subjects receiving silodosin with tadalafil, a selective alpha-1A adrenergic blocker. No significant adverse events related to decreases in blood pressure were observed when a single dose of tadalafil 10 mg or 20 mg was administered to healthy subjects taking 0.4 mg once-daily tamsulosin, another selective alpha-1A adrenergic blocker.

MANAGEMENT: Caution is advised if tadalafil is used in combination with alpha blockers. Patients who demonstrate hemodynamic instability on alpha blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of tadalafil. Therefore, patients should be stable on alpha blocker therapy prior to initiating tadalafil, and tadalafil should be initiated at the lowest recommended dosage. In those patients already on an optimized dosage of tadalafil, alpha blocker therapy should be initiated at the lowest dosage. Clinicians should bear in mind that the safety of tadalafil in combination with alpha blockers may also be affected by other variables such as intravascular volume depletion and use of other antihypertensive medications. The combination of tadalafil and alpha blockers is not recommended for the treatment of benign prostatic hyperplasia (BPH) due to the lack of safety and efficacy data. Patients on alpha blocker therapy for BPH should discontinue the alpha blocker at least one day prior to starting tadalafil for once-daily use in the treatment of BPH.

References
  • "Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals, Corona, CA.
  • "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation, Silver Spring, MD.
  • "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Adcirca

Generic Name: tadalafil

Brand name: Adcirca, Alyq, Cialis

Synonyms: n.a.

Hytrin capsules

Generic Name: terazosin

Brand name: Hytrin

Synonyms: Hytrin

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction